Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.85 USD
+0.07 (9.10%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $0.86 +0.01 (1.06%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Price, Consensus and EPS Surprise
SGMO 0.85 +0.07(9.10%)
Will SGMO be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for SGMO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SGMO
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
SGMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioMarin (BMRN) Gets FDA Nod for Hemophilia A Gene Therapy
FDA Accepts Pfizer's (PFE) Hemophilia B Gene Therapy Filing
Strength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength?
Other News for SGMO
Analysts Conflicted on These Healthcare Names: Veradigm (OtherMDRX), ADC Therapeutics (ADCT) and Sangamo Biosciences (SGMO)
Sangamo Biosciences: A Buy Rating on Strong Gene Therapy and CNS Program Prospects
Truist Financial Sticks to Their Hold Rating for Sangamo Biosciences (SGMO)
Sangamo Biosciences Earns Buy Rating on Breakthrough Brain-Targeting Gene Therapy Capsid and Strategic Advancements
Sangamo Biosciences: Hold Rating Amid Financial Uncertainties and Promising Scientific Developments